Allosteric activation or inhibition of PI3Kγ mediated through conformational changes in the p110γ helical domain

Noah J Harris[1*], Meredith L Jenkins[1*], Sung-Eun Nam[2] Manoj K Rathinaswamy[1],

Matthew AH Parson[1], Harish Ranga-Prasad[1], Udit Dalwadi[2], Brandon E Moeller[1],

Eleanor Sheekey[1], Scott D Hansen[3], Calvin K Yip[2%], and John E Burke[1,2%]

[1]Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, V8W 2Y2, Canada

[2]Department of Biochemistry and Molecular Biology, The University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada

[3]Department of Chemistry and Biochemistry, Institute of Molecular Biology, University of Oregon, Eugene, OR 97403

*These authors contributed equally

%To whom correspondence should be addressed: John E. Burke

Tel: 1-250-721-8732, email: jeburke@uvic.ca

Calvin K. Yip

Tel: 1-604-827-3976, email: calvin.yip@ubc.ca

Abstract

PI3Kγ is a critical immune signaling enzyme activated downstream of diverse cell surface molecules, including Ras, PKCβ activated by the IgE receptor, and Gβγ subunits released from activated GPCRs. PI3Kγ can form two distinct complexes, with the p110γ catalytic subunit binding to either a p101 or p84 regulatory subunit, with these complexes being differentially activated by upstream stimuli. Here using a combination of Cryo electron microscopy, HDX-MS, and biochemical assays we have identified novel roles of the helical domain of p110γ in regulating lipid kinase activity of distinct PI3Kγ complexes. We defined the molecular basis for how an allosteric inhibitory nanobody potently inhibits kinase activity through rigidifying the helical domain and regulatory motif of the kinase domain. The nanobody did not block either p110γ membrane recruitment or Ras/Gβγ binding, but instead decreased ATP turnover. We also identified that p110γ can be activated by dual PKCβ helical domain phosphorylation leading to partial unfolding of an N-terminal region of the helical domain. PKCβ phosphorylation is selective for p110γ-p84 compared to p110γ-p101, driven by differential dynamics of the helical domain of these different complexes. Nanobody binding prevented PKCβ mediated phosphorylation. Overall, this works shows an unexpected allosteric regulatory role of the helical domain of p110γ that is distinct between p110γ-p84 and p110γ-p101, and reveals how this can be modulated by either phosphorylation or allosteric inhibitory binding partners. This opens possibilities of future allosteric inhibitor development for therapeutic intervention.

Introduction

The class I phosphoinositide 3 kinases (PI3Ks) are master regulators of myriad functions through their generation of the lipid signalling molecule phosphatidylinositol 3,4,5-trisphosphate (PIP$_3$) downstream of cell surface receptors (Burke and Williams, 2015; Rathinaswamy and Burke, 2019; Vanhaesebroeck et al., 2021; Vasan and Cantley, 2022). The class I PI3Ks can be further subdivided into the class IA and class IB subfamilies, with class IB PI3Ks being critical in immune signalling, and are composed of a single p110γ catalytic subunit that can bind to either a p101 or p84 regulatory subunit (Hawkins and Stephens, 2015; Lanahan et al., 2022; Okkenhaug, 2013). The two PI3Kγ complexes (either p110γ-p84 or p110γ-p101) play essential and independent roles in both the adaptative and innate immune systems. PI3Kγ has shown promise as a therapeutic target, primarily as an immunomodulator of the tumor microenvironment leading to enhanced anti-tumor immune responses (De Henau et al., 2016; Kaneda et al., 2016b). Multiple isoform selective small molecule ATP competitive inhibitors of p110γ are in clinical trials for multiple forms of human cancers (Li et al., 2021). However, all inhibitors currently developed towards p110γ act as ATP competitive inhibitors, showing equal potency against both p110γ-p84 or p110γ-p101 complexes.

Detailed experiments on the role of p110γ in mice show that knockout of both p101 and p84 leads to PIP$_3$ levels that are equivalent to knockout of p110γ, showing that all cellular PI3Kγ activity requires the presence of either a p84 or p101 regulatory subunit (Rynkiewicz et al., 2020). The two complexes are differentially activated by membrane localised receptors, including G-protein coupled receptors (Li et al., 2000; Stephens et al., 1997), Ras (Jin et al., 2020; Kurig et al., 2009), toll like receptors (TLRs) (Luo et al., 2018), and the IgE antigen receptor (Laffargue et al., 2002; Walser et al., 2013). This leads to the different complexes driving unique immune responses, with p110γ-p101 involved in chemotaxis in neutrophils (Bohnacker et al., 2009; Deladeriere et al., 2015), and p110γ-p84 involved in reactive oxide production. Differential activation of unique PI3Kγ complexes downstream of GPCRs and Ras is caused by the ability of p101 to directly bind to G$\beta\gamma$ subunits downstream of activated GPCRs, with this being lost in

81   p84, making p110γ-p84 activation by Gβγ dependent on Ras mediated membrane

82   recruitment (Rathinaswamy et al., 2023; Kurig et al., 2009; Rynkiewicz et al., 2020).

83   Activation of PI3Kγ downstream of the IgE antigen receptor is driven by calcium mediated

84   activation of protein kinase Cβ, leading to the selective phosphorylation and activation of

85   p110γ at S582 (Walser et al., 2013), with this putatively only occurring in p110γ-p84 and

86   not p110γ-p101. The full molecular mechanisms underlying how phosphorylation of p110γ

87   is selective for different p84 or p101 complexes, and how it activates lipid kinase activity

88   are poorly understood.

89   Extensive biophysical approaches including cryo electron microscopy (cryo-EM),

90   X-ray crystallography, and hydrogen deuterium exchange mass spectrometry (HDX-MS)

91   have provided extensive insight into the molecular underpinnings of how p110γ

92   associates with both p101 and p84, how they are differentially activated by Ras and

93   GPCR signals, and how they can be activated on lipid membranes (Pacold et al., 2000;

94   Walker et al., 1999; Rathinaswamy et al., 2021c, 2021a; Gangadhara et al., 2019; Vadas

95   et al., 2013; Rathinaswamy et al., 2023). The p110γ catalytic subunit is composed of an

96   adaptor binding domain (ABD), a Ras binding domain (RBD), a C2 domain, a helical

97   domain, and a bi-lobal kinase domain (Rathinaswamy et al., 2021a; Walker et al., 1999).

98   A set of helices positioned C-terminal to the activation loop in the kinase domain play a

99   critical role in regulating activity, with this region referred to as the regulatory motif

100 (Rathinaswamy et al., 2021c). The p110γ isoform is unique in that it is inhibited in the

101 absence of a regulatory subunit, with this driven by an autoinhibitory conformation of the

102 regulatory motif, that is proposed to require membrane association to disrupt

103 (Gangadhara et al., 2019). The regulatory motif is a common site of activating mutations

104 in the other class I PI3K isoforms (Jenkins et al., 2023), with p110γ having rare activating

105 oncogenic mutants in this region (Rathinaswamy et al., 2021c). The p110γ subunit

106 interacts with both p84 and p101 at an interface composed of the C2 domain, and the

107 linkers between the RBD-C2 and C2-helical domains (Rathinaswamy et al., 2023, 2021a).

108 The p110γ-p84 complex forms a more dynamic complex compared to p110γ-p101

109 (Rathinaswamy et al., 2023; Shymanets et al., 2013), however, no clear unique regulatory

110 role of this difference in dynamics has been identified.

111 The fundamental roles of p110γ in inflammatory processes has made it a
112 therapeutic target in many pathological conditions, including asthma (Campa et al., 2018),
113 arthritis (Camps et al., 2005), obesity (Becattini et al., 2011; Breasson et al., 2017), and
114 cancer (De Henau et al., 2016; Kaneda et al., 2016a, 2016b). There are significant side
115 effects from non-isoform selective PI3K inhibitors (Bohnacker et al., 2017;
116 Vanhaesebroeck et al., 2021), which has driven the development of highly p110γ selective
117 small molecule inhibitors (Bell et al., 2012; Evans et al., 2016; Gangadhara et al., 2019).
118 However, all p110γ inhibitors will target both p110γ-p101 and p110γ-p84, so there is a
119 potential for the development of allosteric inhibitors outside of the ATP binding site. Initial
120 promise has been reported for the development of class IA p110α oncogene specific
121 allosteric inhibitors. However, further investigation of the molecular mechanisms
122 underlying p110γ regulation will be required for the discovery of regions that can be
123 targeted for allosteric inhibitor development.

124 Here we report critical roles of the helical domain of p110γ in both activation and
125 inhibition of lipid kinase activity. We characterised an allosteric inhibitory nanobody (NB7)
126 that potently inhibits p110γ activity. Cryo-EM was used to define the inhibitory interface,
127 which is composed of the helical domain, the ABD-RBD linker, and the regulatory motif
128 of the kinase domain of p110γ. The region that the nanobody binds to is in close spatial
129 proximity to a previously identified PKCβ phosphorylation site (S582) in the helical
130 domain, and oncogenic activating mutants in the regulatory motif. We fully characterised
131 the activity and dynamics of stoichiometrically PKCβ phosphorylated p110γ, leading to
132 the discovery of a novel additional phosphorylation site (S594/S595). PKCβ
133 phosphorylation was highly selective for p110γ and p110γ-p84, with limited
134 phosphorylation of p110γ-p101. Hydrogen deuterium exchange mass spectrometry
135 (HDX-MS) analysis showed that phosphorylation of p110γ leads to unfolding of the N-
136 terminal region of the helical domain, and increased kinase activity. The presence of the
137 inhibitory nanobody significantly blocks PKCβ phosphorylation, with phosphorylated
138 p110γ showing no detectable binding to NB7. Overall, this work provides unique insight
139 into the critical role of the helical domain in controlling p110γ activity, and how

140   phosphorylation and binding partners can modify this regulation. It also reveals a unique

141   binding site located at the interface of the helical and kinase domain that can be targeted

142   for future allosteric inhibitor design.

143

144   **Results**

145   *Molecular mechanism of nanobody inhibition of p110γ*

146   We previously identified multiple nanobodies that inhibited the activity of p110γ.

147   One from this group (denoted NB7 throughout the manuscript) potently inhibited the

148   membrane mediated activation of p110γ-p84 by both Ras and Gβγ, with HDX-MS

149   experiments mapping the NB7 binding interface to the RBD, helical and kinase domains

150   (Rathinaswamy et al., 2021b). We originally hypothesized that NB7 worked by sterically

151   inhibiting Ras binding to the RBD domain of p110γ. To further explore the molecular

152   mechanism of inhibition we purified all complexes of p110γ (p110γ apo, p110γ-p84,

153   p110γ-p101) along with the NB7 nanobody. The SDS-PAGE of all proteins utilised in this

154   study are shown in the source data file included in the supplemental information.

155   To define the mechanism concerning how NB7 inhibits PI3K activity we analyzed

156   how this nanobody inhibited all class IB PI3K complexes (p110γ, p110γ-p84, p110γ-p101)

157   upon activation by lipidated Gβγ subunits. Intriguingly, we found that all three forms of

158   p110γ were potently inhibited by NB7 (Fig. 1A). While the IC_{50} measured for the three

159   complexes was different, this is likely mainly due to the dramatic difference in protein

160   required to measure lipid kinase activity *in vitro* (~300 nM for p110γ apo/p110γ-p84, and

161   ~10 nM for p110γ-p101, respectively). This suggested that the mechanism of inhibition

162   was not driven by a steric block of Ras association through the RBD, as previously

163   proposed (Rathinaswamy et al., 2021b). We examined the binding of this nanobody to all

164   complexes using biolayer interferometry (BLI). The nanobody bound equivalently tightly

165   to all complexes, with ~2 nM potency for p110γ, p110γ-p84, and p110γ-p101 (Fig. 1B).

166   We also tested binding of the nanobody to all class IA PI3Ks, and there was no detectable

167   binding to p110α, p110β, and p110δ (Fig. 1C).

168   To further understand the mechanism by which this nanobody blocked lipid kinase
169   activity we measured the bulk membrane recruitment dynamics of fluorescently labeled
170   Dy647-p84-p110γ on supported lipid bilayers (SLBs) using Total Internal Reflection
171   Fluorescence (TIRF) Microscopy. We found that the nanobody had no effect on
172   membrane recruitment of p110γ-p84 on bilayers containing membrane-tethered
173   Ras(GTP) and Gβγ (Fig. 1D-F). Membrane binding was not affected when the nanobody
174   was spiked into samples containing membrane associated Dy647-p84-p110γ (Fig 1D).
175   Similarly, pre-incubation of Dy647-p84-p110γ with 500 nM NB7 did not perturb membrane
176   association of the kinase when flowed over a supported membrane (Fig. 1E).

177   We wanted to define the molecular mechanism of how nanobody NB7 was a potent
178   allosteric inhibitor of lipid kinase activity. We purified the complex of nanobody NB7 bound
179   to p110γ-p84 to homogeneity by gel filtration. Using this sample, we obtained a cryo-EM
180   reconstruction of the complex of nanobody (NB7)-bound p110γ at 3.0-Å overall resolution
181   from 149,603 particles (Figs. 2A-D, S1 and supplemental table 1). The density map was
182   of sufficient quality to perform automated and manual construction of the p110γ-NB7
183   complex, with unambiguous building of the interfacial contacts between NB7 and p110γ.
184   Nanobody binding did not induce any large-scale conformational changes of p110γ, as
185   the structure of p110γ bound to NB7 was similar to the apo p110γ crystal structure or
186   p110γ-p101 cryo-EM structure (Fig. S2). The lowest local resolution was in the ABD
187   domain, with increased B-factors of the ABD in the p110γ-NB7 structure compared to
188   p110γ-p101 (Fig. S2). This is consistent with the concept that ABD flexibility plays an
189   important role in class I PI3K regulation (Liu et al., 2022).

190   The interface between NB7 and p110γ was extensive, with ~1200 Å of buried
191   surface area, with interactions of the ABD-RBD linker, N-terminus of the helical domain,
192   and the regulatory motif at the turn between kα8-kα9 (1022-1026aa). This location in the
193   regulatory motif is where both activating oncogenic (R1021C) and inhibitory loss of
194   function mutants have been identified (R1021P) (Takeda et al., 2019), as well as a
195   putative inhibitory phosphorylation site (T1024) (Perino et al., 2011). The resolution was
196   sufficient to unambiguous build the three complementarity determining region (CDR)

loops of NB7 that mediate target selectivity (Fig. 2E-F). The interface is primarily hydrophobic, with only 8 hydrogen bonds, and 1 electrostatic interaction among the 33 interfacial residues of NB7. A pocket formed between the helical domain and the ABD-RBD linker forms the majority of the interface, with extensive interactions with the long CDR3. The CDR1 loop packed up against the N-terminal section of the helical domain, with the CDR2 loop forming the interface with the regulatory motif. Previous study of oncogenic mutants in the regulatory motif of p110γ showed that increased dynamics mediated by these mutants increased kinase activity, putatively by breaking the autoinhibitory tryptophan lock in kα12 of the regulatory motif. Therefore, rigidifying the regulatory motif likely explains the molecular basis for how it prevents kinase activity. The nanobody interface is distinct from the predicted G$\beta\gamma$ interface (Rathinaswamy et al., 2023) and the experimentally resolved Ras interface (Pacold et al., 2000), explaining why it can still be membrane recruited by these stimuli.

p110γ activation by helical domain phosphorylation

To further understand the potential role helical domain dynamics in regulating p110γ activity we searched for any possible regulatory roles of this in PI3K signalling. It has been previously identified that p110γ is directly phosphorylated by the protein kinase PKCβ on residue S582 in the helical domain (Walser et al., 2013). S582 is located on the interior of the helical domain, and would not be expected to be exposed when the N-terminal region of the helical domain is folded (Fig. 3A). To understand this better at a molecular level, we purified a catalytic fragment of PKCβ and performed protein phosphorylation reactions on p110γ apo, p110γ-p84, and p110γ-p101. We identified a phosphorylated peptide containing S582, and surprisingly, we found an additional p110γ phosphorylation site at S594/S595 (Fig. 3B, Fig. S3). The S594/S595 site is also located in the N-terminal region of the helical domain, and is even more buried than S582, and would not be expected to be exposed when this region is folded (Fig. 3A). Dose response curves of PKCβ treatment were carried out for p110γ (Fig. 3C), p110γ-p84 (Fig. 3D), and p110γ-p101 (Fig. 3E). Both p110γ and p110γ-p84 showed similar dose response curves

226   for PKCβ treatment, with similar curves for S582 and S594/S595. The p110γ-p101
227   complex was only very weakly phosphorylated, with <100-fold lower levels compared to
228   p110γ and p110γ-p84 (Fig. 3E). This is consistent with the helical domain in p110γ being
229   more rigid when bound to p101, compared to either bound to p84 or p110γ alone.

230   To provide additional insight into the molecular mechanisms underlying p110γ
231   phosphorylation we carried out hydrogen deuterium exchange mass spectrometry (HDX-
232   MS) experiments on p110γ and phosphorylated p110γ (90.8% phosphorylated S594/595,
233   92% phosphorylated S582) (Fig. 4A). The full data underlying the experiment is available
234   in the source data, and data processing information is in supplemental table 2. We have
235   previously observed that the N-terminal region of the helical domain of apo p110γ
236   (residues spanning 557-630aa) shows isotope profiles that are consistent with EX1 H/D
237   exchange kinetics (Rathinaswamy et al., 2021b, 2021c; Vadas et al., 2013; Walser et al.,
238   2013). This is indicative of cooperative unfolding of extended protein regions, with H/D
239   exchange occurring faster than the refolding event. This region is where the PKC
240   phosphorylation sites are located, and may explain how the buried residues S582 and
241   S594/S595 can be exposed to PKC. This is compatible with the observation that p110γ-
242   p101 is protected from phosphorylation, as it does not show EX1 kinetics in this region,
243   whereas both p110γ and p110γ-p84 do (Rathinaswamy et al., 2021a).

244   When we compared phosphorylated p110γ (>90.8% as measured by mass
245   spectrometry at both sites) to unphosphorylated p110γ we observed extensive increases
246   in dynamics in the C2, helical domain and kinase domain (Fig. 4A-D). The largest
247   increases in exchange upon phosphorylation were located in the N-terminal region of the
248   helical domain, with the peptides directly adjacent to the phosphorylation site showing
249   almost complete deuterium incorporation at the earliest time points of exchange. This is
250   indicative of significant disruption of the alpha helical secondary structure in this region.
251   When we examined the exchange profiles in this region they still underwent EX1 kinetics
252   (Fig. 4C), however, phosphorylated p110γ was enriched in the more fully deuterated
253   species. In addition to the regions in the helical domain, a portion of the regulatory motif
254   of the kinase domain also showed increased deuterium exposure. This included the kα9-

255 kα12 helices that surround the activation loop of p110γ. These increases in exchange

256 were similar to those we had observed in a R1021C oncogenic activating mutant of

257 *PIK3CG* (Rathinaswamy et al., 2021c*)*.

258   To further explore the potential role of phosphorylation in mediating p110γ activity,

259 we examined the kinase activity of p110γ for both basal ATPase and lipid membranes.

260 Assays measured the hydrolysis of ATP to ADP, with this acting as a surrogate for PIP$_3$

261 production in the membrane assay. PKCβ-mediated phosphorylation enhanced the

262 ATPase activity of p110γ ~2-fold in both the absence and presence of membranes (Fig.

263 4E).

264

265 *Nanobody blocks p110γ phosphorylation*

266   As NB7 bound at the interface of the helical and kinase domains that is exposed

267 upon PKC phosphorylation of p110γ we hypothesized that the nanobody would likely alter

268 phosphorylation. We carried out PKC phosphorylation of p110γ, p110γ-p101 and p110γ

269 bound to NB7. The presence of NB7 showed even lower phosphorylation than p110γ-

270 p101, with almost complete abrogation of phosphorylation at both sites (Fig. 5A-B). We

271 also wanted to determine whether p110γ phosphorylation reciprocally perturbed NB7

272 binding. BLI experiments showed that there was no detectable binding of NB7 to

273 phosphorylated p110γ (Fig. 5C-D), consistent with phosphorylation disrupting the N-

274 terminal region of the p110γ helical domain. In addition, lipid kinase assays using

275 phosphorylated p110γ showed no detectable difference in activity when measured in the

276 absence and presence nanobody (Fig. 5E).

277

278 **Discussion**

279   Here we find that the helical domain is a central regulator of the p110γ catalytic

280 subunit of class IB PI3K, with modulation of helical dynamics through binding partners or

281 PTMs able to either increase or decrease lipid kinase activity. These results expand on

282 previous work defining the helical domain as a central regulator of class IA PI3Ks, where

283 the nSH2 domain of the p85 regulatory subunits makes inhibitory interactions that

10

284 significantly inhibit lipid kinase activity of all class IA catalytic subunits (p110α, p110β,

285 and p110δ) (Mandelker et al., 2009; Miled et al., 2007; Burke and Williams, 2013; Burke,

286 2018). This inhibitory interaction in class IA PI3Ks is disrupted in human cancers (helical

287 hotspot mutations in *PIK3CA*) (Samuels et al., 2004) and immune disorders (helical

288 mutations in *PIK3CD* in APDS1) (Angulo et al., 2013; Lucas et al., 2014). Class IB PI3Ks

289 are unique compared to class IA PI3Ks, as they are not inhibited by p101 and p84

290 regulatory subunits, but instead potentiate GPCR activation. This lack of inhibition is due

291 to the distinct binding interface of class IB PI3K regulatory subunits compared to class IA

292 regulatory subunits, with only class IA regulatory subunits making direct inhibitory

293 interactions with the kinase and helical domains of p110 catalytic subunits

294 (Rathinaswamy et al., 2021a). Here we show that a unique surface at the interface of the

295 helical and kinase domains of p110γ is a potential site for the development of novel

296 allosteric inhibitors that modulate p110γ activity.

297 The previously identified inhibitory nanobody (NB7) (Rathinaswamy et al., 2021b)

298 bound with high affinity and inhibited all complexes of p110γ. The nanobody interface is

299 distinct from how the nSH2 inhibits class IA PI3K activity, as its binding site is on the

300 opposite face of the helical domain (Fig. 6A). The mechanism of inhibition is also distinct,

301 as the nSH2-helical interaction plays a critical role in preventing membrane recruitment

302 of inhibited class I PI3Ks, with removal of this interface either through pYXXM motif

303 binding, or oncogenic mutations leading to increased membrane recruitment (Burke et

304 al., 2012, 2011; Zhang et al., 2011). Analysis of the nanobody binding site compared to

305 the structure of HRas-p110γ or the HDX-MS supported Alphafold-multimer prediction of

306 G$\beta\gamma$-p110γ (Rathinaswamy et al., 2023) shows that nanobody binding does not sterically

307 block complex formation (Fig. 6B). This is consistent with it not blocking membrane

308 recruitment by Ras/G$\beta\gamma$.The nanobody inhibited ATP turnover both in solution and on

309 membranes, suggesting that it prevents formation of a catalytically competent

310 conformation of p110γ, but still allows for membrane recruitment. Further development of

311 small molecule allosteric binding partners in this allosteric pocket between the kinase and

312 helical domain may reveal the specific molecular interactions in this pocket that mediate

313 inhibition.

314   Oncogenic mutations are frequent in the class IA PI3Kα encoded by *PIK3CA*, with

315   this being the 2nd most frequently mutated gene in human cancer (Lawrence et al., 2014).

316   Mutations in p110γ encoded by *PIK3CG* in cancer are less frequent, however, they can

317   still provide insight into regulatory mechanisms that control activity. Oncogenic mutations

318   in the kinase domain (R1021C) and helical domain (E581K) are in close proximity to the

319   nanobody binding site, and both would be expected to disrupt the stability of the helical

320   domain or regulatory motif of the kinase domain (Fig. 6C). In addition to these mutations

321   there are also multiple post-translational modifications that occur in this region, including

322   inhibitory phosphorylation at T1024 (Perino et al., 2011), and activating phosphorylation

323   at S582 (Walser et al., 2013). PKCβ is activated downstream of the IgE receptor in mast

324   cells (Walser et al., 2013), but the full details of how this activates PI3K has been unclear.

325   We identified an additional PKCβ phosphorylation site located in the helical domain

326   (S594/S595) (Fig. 6C). Both the S582 and S594/S595 sites are not surface accessible

327   and would require a transient opening of the helical domain for kinase accessibility. HDX-

328   MS analysis of the helical domain of p110γ has shown that it is more dynamic than other

329   class I PI3K isoforms (Burke and Williams, 2013; Walser et al., 2013), with the presence

330   of the p101 regulatory subunit dramatically decreasing helical domain dynamics (Vadas

331   et al., 2013). This putative mechanism of helical domain dynamics driving PKCβ

332   phosphorylation is consistent with our observation that p101 subunits decreased p110γ

333   phosphorylation >100-fold. PKCβ phosphorylation of p110γ leads to increased dynamics

334   in both the helical and kinase domains with increased kinase activity, although only

335   weakly compared to full activation by either membrane localised Ras or G$\beta\gamma$. This

336   increase was observed with both membrane and soluble substrate, so likely is not driven

337   by altered membrane recruitment.

338   Overall, our biophysical and biochemical analysis of modulators of helical domain

339   dynamics reveal the critical role of this domain in regulating class IB PI3K activity. This

340   raises possibilities for development of small molecule modulators that may either increase

341   or decrease helical domain dynamics, leading to either activation or inhibition. The high-

342   resolution structure of an allosteric inhibitor nanobody provide initial insight into which

343   pockets can specifically be targeted. Multiple ATP competitive p110γ selective inhibitors

344 are in clinical trials for human cancers (Li et al., 2021), with many having significant side

345 effects. The identification of novel inhibitory strategies provides new opportunities for

346 targeting p110γ dysregulation in human disease.

347

348 **Acknowledgements**

361

362 **Conflict of Interest statement**

363 JEB reports personal fees from Scorpion Therapeutics, Reactive therapeutics and

364 Olema Oncology; and research grants from Novartis. Other authors declare no competing

365 interests.

366

367 **Methods**

Resources table	SOURCE	IDENTIFIER
Bacterial and virus strains		
E.coli XL10-GOLD KanR Ultracompetent Cells	Agilent	200317
E.coli DH10EMBacY Competent Cells	Geneva Biotech	DH10EMBacY
Chemicals, peptides, and recombinant proteins		
Deuterium Oxide 99.9%	Sigma	151882
Guanosine 5′-diphosphate (GDP) sodium salt hydrate	Sigma	G7127-100MG
Guanosine 5′-triphosphate (GTP) sodium salt hydrate	Sigma	G8877-250MG
Sodium deoxycholate	Sigma	D6750

Polyoxyethylene (10) lauryl ether	Sigma	P9769
CHAPS, Molecular Biology Grade	EMD Millipore	220201
Phosphatidylserine (Porcine Brain)	Avanti	840032C
Phosphatidylethanolamine (Egg yolk)	Sigma	P6386
Cholesterol	Sigma	47127-U
Phosphatidylcholine (Egg yolk)	Avanti	840051C
Phosphatidylinositol-4,5-bisphosphate (Porcine Brain)	Avanti	840046
Sphingomyelin (Egg yolk)	Sigma	S0756
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC)	Avanti	850375C
1,2-dioleoyl-*sn*-glycero-3-phospho-L-serine (18:1, DOPS)	Avanti	840035C
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[4-(p-maleimidomethyl)cyclohexane-carboxamide] (18:1 MCC-PE)	Avanti	780201C
10 mg/mL beta casein solution	ThermoFisher	37528
10x PBS [pH 7.4]	Corning	46-013-CM
glucose oxidase from *Aspergillus niger* (225 U/mg)	Biophoretics	B01357.02
catalase	Sigma	C40-100MG Bovine Liver
Trolox	Cayman Chemicals	10011659
Dyomics 647 maleimide dye	Dyomics	647P1-03
Coenzyme A	Sigma	C3019
Sulfuric acid	Sigma	58105-2.5L-PC
C-Flat 2/2-T grids	FisherScientific	50-192-8327
Critical commercial assays		
Transcreener ADP2 FI Assay (1,000 Assay, 384 Well)	BellBrook Labs	3013-1K
Deposited data		
PDB coordinate file for p110γ-NB7 structure	PDB	8DP0
EM density file for p110γ-NB7 complex	EMD	EMD-27627
HDX-MS and phosphorylation proteomics data	PRIDE	PXD040765
Oligonucleotides		
Fwd primer for amplifying KD of PKCβII GTATTTTCAGGGCgccggtaccACGACCAACACTGTCTCCAAATTTG	Sigma	MR51F
Rvs primer for amplifying KD of PKCβII gactcgagcggccgcTTATAGCTCTTGACTTCGGGTTTTAAAAATTCAG	Sigma	MR51R
Fwd primer for amplifying N term of PKCβII CCATCACggatctggcggtagtATGGCTGACCCGGCTGCG	Sigma	MR52F
Rvs primer for amplifying N term of PKCβII GCCCTGAAAATACAGGTTTTCCTTTTCTTCCGGGACCTTGGTTCCC	Sigma	MR52R
Fwd primer for adding stop codon to PKCβII AGTCAAGAGCTAAgcggccgctcgagtctagagcctgc	Sigma	MR56F
Rvs primer for adding stop codon to PKCβII gactcgagcggccgcTTAGCTCTTGACTTCGGGTTTTAAAAATTCAG	Sigma	MR56R
Recombinant DNA		
pMultiBac-Gβ1/Gγ2	PMID:34452907	pOP737

pACEBac1-hsp110γ	PMID:34452907	MR30
pMultiBac-hsp110γ-ssp101	PMID:34452907	MR22
pMultiBac-hsp110γ-mmp84	PMID:34452907	MR24
pFastBac HRas G12V	PMID:34452907	BS9
biGBac hsp110γ/ybbr-hsp84	PMID:36842083	HP28
biGBac hsp110γ/ybbr-hsp101	PMID:36842083	HP29
his6-GST-PrescissionProtease-SNAP-RBD(K65E)	PMID:34452907	pSH936
his6TEV-HRas(1-184aa) C118S, C181S	PMID:34452907	pSH414
his6-Gγ2, SNAP-Gβ1 (DUAL FastBac)	PMID:34452907	pSH651
pACEBAC-PKCβII (internal tev cleavage site)	This paper	pMR56
pFASTBac p110α	PMID: 28515318	pOV1181
pFASTBac p110β	PMID: 28515318	pOV1182
pFASTBac p110δ	PMID: 28515318	pOV1183
pFASTBac p85β	This paper	EX21
Software and algorithms		
COOT-0.9.4.1	CCP4	https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/
Phenix-1.19.1	Open source	https://www.phenix-online.org/
PDBePISA (Proteins, Interfaces, Structures and Assemblies)	EMBL-EBI	https://www.ebi.ac.uk/pdbe/pisa/pistart.html
ESPript 3.0	Robert et al NAR 2014	https://espript.ibcp.fr
HDExaminer	Sierra Analytics	http://massspec.com/hdexaminer
GraphPad Prism 7	GraphPad	https://www.graphpad.com
PyMOL	Schroedinger	http://pymol.org
Compass Data Analysis	Bruker	https://www.bruker.com
ChimeraX	UCSF	https://www.rbvi.ucsf.edu/chimerax/
ImageJ/Fiji	ImageJ	https://imagej.net/software/fiji/
Nikon NIS elements	Nikon	https://www.microscope.healthcare.nikon.com/products/software/nis-elements
cryoSPARC v.3.3.2	Structura Biotechnology	https://cryosparc.com/
Other		
Sf9 insect cells for expression	Expression Systems	94-001S
Insect cell media	Expression Systems	96-001-01
Hellmanex III cleaning solution	Fisher	14-385-864
6-well sticky-side chamber	IBIDI	80608

368

369

Plasmid Generation

371 Plasmids encoding Homo sapiens p110γ (human), Mus musculus p84 (mouse), Sus scrofa p101 (porcine), and Gβγ were used as previously described (Rathinaswamy et al., 2023, 2021a). The class IA plasmids were also used as previously described (Dornan et al., 2017; Siempelkamp et al., 2017). The pDONR223-PRKCB2 (PKCβII, uniprot identifier: P05771-2) was a gift from William Hahn & David Root (Addgene plasmid #23746; http://n2t.net/addgene: 23746; RRID:Addgene_23746) (Johannessen et al., 2010). The PKCβII construct contains an internal TEV site that cleaves the catalytic domains from the C1/C2 regulatory domains (TEV site inserted between residues 320 and 321 of PRKCB, uniprot identifier: P05771-2) and it was subcloned into a pACEBAC Sf9 expression vector for protein purification. For purification, a 10× histidine tag, a 2× strep tag, and a tobacco etch virus protease cleavage site were cloned to the N terminus of the regulatory subunits for the complex and to p110γ and PKCβII for constructs without regulatory subunits. Full details of the plasmids are included in the resource table.

384

Virus Generation and Amplification:

386 The plasmids encoding genes for insect cell expression were transformed into DH10MultiBac cells (MultiBac, Geneva Biotech) to generate baculovirus plasmid (bacmid) containing the genes of interest. Successful generation was identified by blue-white colony screening and the bacmid was purified using a standard isopropanol-ethanol extraction method. Bacteria were grown overnight (16 hours) in 3-5 mL 2xYT (BioBasic #SD7019). Cells were spun down and the pellet was resuspended in 300 µL of 50 mM Tris-HCl, pH 8.0, 10 mM EDTA, 100 mg/mL RNase A. The pellet was lysed by the addition of 300 µL of 1% sodium dodecyl sulfate (SDS) (W/V), 200 mM NaOH, and the reaction was neutralized by addition of 400 µL of 3.0 M potassium acetate, pH 5.5. Following centrifugation at 21130 RCF and 4 °C (Rotor #5424 R), the supernatant was mixed with 800 µL isopropanol to precipitate bacmid DNA. Following centrifugation, the pelleted bacmid DNA was washed with 500 µL 70% Ethanol three times. The pellet was then air dried for 1 minute and re-suspended in 50 µL Buffer EB (10 mM Tris-Cl, pH 8.5; All buffers

399   from QIAprep Spin Miniprep Kit, Qiagen #27104). Purified bacmid was then transfected

400   into Sf9 cells. 2 mL of Sf9 cells at 0.6X10⁶ cells/mL were aliquoted into a 6-well plate and

401   allowed to attach to form a confluent layer. Transfection reactions were prepared mixing

402   8-12 µg of bacmid DNA in 100 µL 1xPBS and 12 µg polyethyleneimine

403   (Polyethyleneimine "Max" MW 40.000, Polysciences #24765, USA) in 100 µL 1xPBS and

404   the reaction was allowed to proceed for 20-30 minutes before addition to an Sf9

405   monolayer containing well. Transfections were allowed to proceed for 5-6 days before

406   harvesting virus containing supernatant as a P1 viral stock.

407   Viral stocks were further amplified by adding P1 to Sf9 cells at ~2x10⁶ cells/mL

408   (2/100 volume ratio). This amplification was allowed to proceed for 4-5 days and resulted

409   in a P2 stage viral stock that was used in final protein expression. Harvesting of P2 viral

410   stocks was carried out by centrifuging cell suspensions in 50 mL Falcon tubes at 2281

411   RCF (Beckman GS-15). To the supernatant containing virus, 5-10% inactivated fetal

412   bovine serum (FBS; VWR Canada #97068-085) was added and the stock was stored at

413   4°C.

414

415   *Expression and purification of PI3Kγ, PI3Kα/β/δ and PKCβ constructs:*

416   PI3Kγ and PKCβ constructs were expressed in Sf9 insect cells using the baculovirus

417   expression system. Following 55 hours of expression, cells were harvested by

418   centrifuging at 1680 RCF (Eppendorf Centrifuge 5810 R) and the pellets were snap-

419   frozen in liquid nitrogen. The complex was purified through a combination of nickel affinity,

420   streptavidin affinity and size exclusion chromatographic techniques.

421   Frozen insect cell pellets were resuspended in lysis buffer (20 mM Tris pH 8.0, 100

422   mM NaCl, 10 mM imidazole pH 8.0, 5% glycerol (v/v), 2 mM βME), protease inhibitor

423   (Protease Inhibitor Cocktail Set III, Sigma)) and sonicated for 2 minutes (15s on, 15s off,

424   level 4.0, Misonix sonicator 3000). Triton-X was added to the lysate to a final

425   concentration of 0.1% and clarified by spinning at 15,000 RCF at 4°C for 45 minutes

426   (Beckman Coulter JA-20 rotor). The supernatant was loaded onto a 5 mL HisTrap™ FF

427   crude column (GE Healthcare) equilibrated in NiNTA A buffer (20 mM Tris pH 8.0, 100

428   mM NaCl, 20 mM imidazole pH 8.0, 5% (v/v) glycerol, 2 mM βME). The column was

429 washed with high salt NiNTA A buffer (20 mM Tris pH 8.0, 1 M NaCl, 20 mM imidazole

430 pH 8.0, 5% (v/v) glycerol, 2 mM βME), NiNTA A buffer, 6% NiNTA B buffer (20 mM Tris

431 pH 8.0, 100 mM NaCl, 250 mM imidazole pH 8.0, 5% (v/v) glycerol, 2 mM βME) and the

432 protein was eluted with 100% NiNTA B. The eluent was loaded onto a 5 mL StrepTrap™

433 HP column (GE Healthcare) equilibrated in gel filtration buffer (20mM Tris pH 8.5, 100

434 mM NaCl, 50 mM Ammonium Sulfate and 0.5 mM TCEP). To purify *PI3Kα/β/δ*, the

435 purification protocol was performed as described above but instead the protein was eluted

436 in PI3Ka gel filtration buffer (20mM HEPES 7.5, 150mM NaCl, 0.5mM TCEP). The column

437 was washed with the corresponding gel filtration buffer and loaded with tobacco etch virus

438 protease. After cleavage on the column overnight, the PI3Kγ protein constructs were

439 eluted in gel filtration buffer. The protein was concentrated in a 50,000 MWCO Amicon

440 Concentrator (Millipore) to <1 mL and injected onto a Superdex™ 200 10/300 GL

441 Increase size-exclusion column (GE Healthcare) equilibrated in gel filtration buffer. After

442 size exclusion, the protein was concentrated, aliquoted, frozen, and stored at -80ºC. For

443 PKCβ, the protein was eluted from the strep column in gel filtration buffer, and the eluate

444 was then loaded on a 1ml HisTrap™ FF column to remove the his tagged LipTev. The

445 flowthrough was collected, and the column was washed with 2ml of gel filtration buffer.

446 These fractions were pooled and concentrated and stored at -80ºC.

447   To purify phosphorylated p110γ, the purification protocol as described above was

448 performed but PKCβ was added to the strep column at a molar ratio of 1:3 (PKCβII:p110)

449 along with LipTEV, 20 mM MgCl$_2$ and 1mM ATP and allowed to incubate on ice for 4

450 hours. The protein was eluted by adding 7 ml of gel filtration buffer and treated with a

451 second dose of PKCβ (same ratio as above) and allowed to incubate on ice for another

452 3 hours. For non-phosphorylated p110, same protocol was followed with the exception in

453 the addition of PKCβ. Both the proteins were concentrated in a 50,000 MWCO Amicon

454 Concentrator (Millipore) to <1 mL and injected onto a Superdex™ 200 10/300 GL

455 Increase size-exclusion column (GE Healthcare) equilibrated in gel filtration buffer. The

456 final phosphorylation level of the two sites was characterised by mass spectrometry, with

457 these values being 92% and 90.8%, for S582 and S594/S595 respectively. After size

458 exclusion, the protein was concentrated, aliquoted, frozen, and stored at -80ºC.

459

Expression and Purification of lipidated G$\beta\gamma$ for kinase activity assays:

Full length, lipidated human *G$\beta\gamma$* (Gβ1γ2) was expressed in Sf9 insect cells and purified as described previously. After 65 hours of expression, cells were harvested, and the pellets were frozen as described above. Pellets were resuspended in lysis buffer (20 mM HEPES pH 7.7, 100 mM NaCl, 10 mM βME, protease inhibitor (Protease Inhibitor Cocktail Set III, Sigma)) and sonicated for 2 minutes (15s on, 15s off, level 4.0, Misonix sonicator 3000). The lysate was spun at 500 RCF (Eppendorf Centrifuge 5810 R) to remove intact cells and the supernatant was centrifuged again at 25,000 RCF for 1 hour (Beckman Coulter JA-20 rotor). The pellet was resuspended in lysis buffer and sodium cholate was added to a final concentration of 1% and stirred at 4°C for 1 hour. The membrane extract was clarified by spinning at 10,000 RCF for 30 minutes (Beckman Coulter JA-20 rotor). The supernatant was diluted 3 times with NiNTA A buffer (20 mM HEPES pH 7.7, 100 mM NaCl, 10 mM Imidazole, 0.1% C12E10, 10mM βME) and loaded onto a 5 mL HisTrap™ FF crude column (GE Healthcare) equilibrated in the same buffer. The column was washed with NiNTA A, 6% NiNTA B buffer (20 mM HEPES pH 7.7, 25 mM NaCl, 250 mM imidazole pH 8.0, 0.1% C12E10, 10 mM βME) and the protein was eluted with 100% NiNTA B. The eluent was loaded onto HiTrap™ Q HP anion exchange column equilibrated in Hep A buffer (20 mM Tris pH 8.0, 8 mM CHAPS, 2 mM Dithiothreitol (DTT)). A gradient was started with Hep B buffer (20 mM Tris pH 8.0, 500 mM NaCl, 8 mM CHAPS, 2 mM DTT) and the protein was eluted in ~50% Hep B buffer. The eluent was concentrated in a 30,000 MWCO Amicon Concentrator (Millipore) to < 1 mL and injected onto a Superdex™ 75 10/300 GL size exclusion column (GE Healthcare) equilibrated in Gel Filtration buffer (20 mM HEPES pH 7.7, 100 mM NaCl, 10 mM CHAPS, 2 mM TCEP). Fractions containing protein were pooled, concentrated, aliquoted, frozen and stored at -80 °C.

485

Expression and purification of nanobody:

Nanobody NB7-PIK3CG with a C-terminal 6X His tag was expressed from a pMESy4 vector in the periplasm of WK6 *E.coli*. A 1L culture was grown to OD600 of 0.7

489 in Terrific Broth containing 0.1% glucose and 2mM MgCl2 in the presence of 100 μg/mL

490 ampicillin and was induced with 0.5 mM isopropyl-β-D-thiogalactoside (IPTG). Cells were

491 harvested the following day by centrifuging at 2500 RCF (Eppendorf Centrifuge 5810 R)

492 and the pellet was snap-frozen in liquid nitrogen. The frozen pellet was resuspended in

493 15 mL of TES buffer containing 200 mM Tris pH 8.0, 0.5mM ethylenediaminetetraacetic

494 acid (EDTA) and 500 mM Sucrose and was mixed for 45 minutes at 4°C. To this mixture,

495 30 mL of TES buffer diluted four times in water was added and mixed for 45 minutes at

496 4°C to induce osmotic shock. The lysate was clarified by centrifuging at 14,000 rpm for

497 15 minutes (Beckman Coulter JA-20 rotor). Imidazole was added to the supernatant to

498 final concentration of 10mM loaded onto a 5 mL HisTrap™ FF crude column (GE

499 Healthcare) equilibrated in NiNTA A buffer (20 mM Tris pH 8.0, 100 mM NaCl, 20 mM

500 imidazole pH 8.0, 5% (v/v) glycerol, 2 mM β-mercaptoethanol (βME)). The column was

501 washed with high salt NiNTA A buffer (20 mM Tris pH 8.0, 1 M NaCl, 20 mM imidazole

502 pH 8.0, 5% (v/v) glycerol, 2 mM βME), followed by 100% NiNTA A buffer, then a 6%

503 NiNTA B wash buffer (20 mM Tris pH 8.0, 100 mM NaCl, 250 mM imidazole pH 8.0, 5%

504 (v/v) glycerol, 2 mM βME) and the protein was eluted with 100% NiNTA B. The eluent

505 was concentrated in a 10,000 MWCO Amicon Concentrator (Millipore) to <1 mL and

506 injected onto a Superdex™ 75 10/300 GL Increase size-exclusion column (GE

507 Healthcare) equilibrated in gel filtration buffer (20mM Tris pH 8.5, 100 mM NaCl, 50 mM

508 Ammonium Sulfate and 0.5 mM tris(2-carboxyethyl) phosphine (TCEP)). Following size

509 exclusion, the protein was concentrated, frozen and stored at -80°C.

510

511 *Phosphorylation analysis*

512 For the dose–response phosphorylation of p110γ, p110/p84, and p110/p101, each

513 protein or complex (750nM) was mixed with ATP (200 μM), GFB (20mM Tris pH 8.5, 100

514 mM NaCl, 50 mM Ammonium Sulfate and 0.5 mM TCEP), MgCl$_2$(20mM) and various

515 amounts of PKC (4 μg, 800 ng, 160 ng, 32 ng, 6.4 ng, and 0 ng). Reactions were

516 incubated for three hours on ice and quenched with 50 μL of ice-cold acidic quench buffer

517 (0.7 M guanidine-HCl, 1% formic acid). followed by immediate freezing using liquid

518 nitrogen and storage at –80 °C.

519   For the experiment studying the effect of nanobody on phosphorylation, p110γ or

520 p110/p101, (500nM) was mixed with ATP (1 mM), GFB (20mM Tris pH 8.5, 100 mM NaCl,

521 50 mM Ammonium Sulfate and 0.5 mM TCEP), $MgCl_2$(20mM), with nanobody and PKC

522 present at 1200 nM and 500nM, respectively. Reactions were incubated for one hour at

523 room temperature and quenched with 54 μL of ice-cold acidic quench buffer (0.7 M

524 guanidine-HCl, 1% formic acid) followed by immediate freezing using liquid nitrogen and

525 storage at –80 °C.

526   Phosphorylation of all proteins was confirmed using Mass spectrometry and

527 PEAKS7 analysis. The phosphorylated and non-phosphorylated peptide ratios were

528 determined by generating extracted ion chromatograms for each peptide using their

529 molecular formula and charge state in the Bruker Compass Data Analysis software. The

530 area under each extracted curve was then extracted. The full MS quantification of each

531 of the phosphorylated and non-phosphorylated peptide is provided in the source data.

532

533

534 *Lipid vesicle preparation for kinase activity assays*

535 Lipid vesicles containing 5% brain phosphatidylinositol 4,5- bisphosphate (PIP2), and

536 95% brain phosphatidylserine (PS), were prepared by mixing the lipids solutions in

537 organic solvent. The solvent was evaporated in a stream of argon following which the lipid

538 film was desiccated in a vacuum for 45 minutes. The lipids were resuspended in lipid

539 buffer (20 mM HEPES pH 7.0, 100 mM NaCl and 10 % glycerol) and the solution was

540 vortexed for 5 minutes followed by sonication for 15 minutes. The vesicles were then

541 subjected to ten freeze thaw cycles and extruded 11 times through a 100-nm filter (T&T

542 Scientific: TT-002-0010). The extruded vesicles were sub-aliquoted and stored at -80°C.

543 Final vesicle concentration was 2 mg/mL.

544

545 *Kinase Assays*

546 All kinase assays were done using Transcreener ADP2 Fluorescence Intensity (FI)

547 assays (Bellbrook labs) which measures ADP production. All assays used super-lipid

548 vesicles [5% phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2), and 95%

549 phosphatidylserine (PS)] at final concentration of 0.5 mg/mL, and ATP at a final
550 concentration of 100 µM.

551 For assays measuring the inhibition by nanobody, 4X kinase (final concentration:
552 330 nM for p110γ, 300nM for p110γ/p84 and 12nM for p110γ/p101) was mixed with
553 varying 4X concentrations of nanobody (final concentration: 2µM – 2.7nM) or kinase
554 buffer (20mM HEPES pH 7.5, 100mM NaCl, 3mM MgCl$_2$, 0.03% CHAPS, 2mM TCEP,
555 and 1mM EGTA) and allowed to sit on ice for 15 minutes. 2 µl of protein mix was mixed
556 with 2 µl of lipid solution containing G$\beta\gamma$ (1µM final concentration), ATP (100 µM), Super
557 lipid (0.5mg/ml final concentration), and lipid buffer (25mM HEPES pH 7, 5% Glycerol,
558 and 100mM NaCl) and incubated at room temperature for 60 minutes.
559 For assays comparing the difference in activation between phosphorylated and non-
560 phosphorylated p110γ, 2X kinase (final concentrations: 1µM – 12.3nM) was mixed with
561 2X lipid solutions containing ATP (100 µM), and lipid buffer and either nanobody (3 µM
562 final concentration), Super lipid (0.5mg/ml final concentration) or both nanobody and lipid.
563 The reaction was incubated at room temperature for 60 minutes.

564 After the 60-minute incubation, all reactions were stopped with 4 µL of 2X stop and
565 detect solution containing Stop and Detect buffer (20mM HEPES,0.02% Brij-35, 400mM
566 40mM EDTA pH 7.5), 8 nM ADP Alexa Fluor 594 Tracer and 93.7 µg/mL ADP2 Antibody
567 IRDye QC-1, covered and incubated at room temperature for 1 hr before reading the
568 fluorescence. The fluorescence intensity was measured using a SpectraMax M5 plate
569 reader at excitation 590 nm and emission 620 nm. All data was normalized against the
570 appropriate measurements obtained for 100 µM ATP and 100 µM ADP with no kinase.
571 The percent ATP turnover was interpolated using a standard curve (0.1-100 µM ADP).
572 Interpolated values were then used to calculate the specific activity of the enzyme.

573

574 *Biolayer interferometry*
575 All Biolayer interferometry experiments were performed using the Octet K2 (Fortebio Inc.).
576 When comparing nanobody binding to each complex, His-tagged nanobody was
577 immobilized on an Anti-Penta-His biosensor for 600s, and the sensor was dipped into
578 solutions of varying concentrations of p110γ, p110p84, and p110p101 (50 nM – 1.9 nM)

579 for 600s followed by a 1200s dissociation step in Octet Buffer (20 mM tris pH 8.5, 100

580 mM NaCl, 50 mM ammonium sulfate, 0.1% bovine serum albumin, and 0.02% Tween

581 20). Experiments comparing class IA PI3K versus class IB PI3K used 500 nM nanobody

582 loaded on the Octet tip, and 50 nM of PI3Ks. When comparing nanobody binding to

583 phosphorylated and unphosphorylated p110γ, His-tagged nanobody was immobilized on

584 an Anti-Penta-His biosensor for 600 s, and the sensor was dipped into solutions of either

585 phosphorylated or non-phosphorylated p110γ at a final concentration of 25 nM for 600s

586 followed by a dissociation step for 600s. The average K_D (dissociation constant) was

587 calculated from the binding curves based on their global fit to a 1:1 binding model.

588

589 *Supported lipid bilayer TIRF microscopy experiments*

590 The membrane binding dynamics of Dy647-p84-p110γ were measured in the

591 absence and presence of nanobody 7 (NB7) using TIRF microscopy. As previously

592 described (Rathinaswamy et al., 2023), supported lipid bilayers were formed using 50 nm

593 extruded small unilamellar vesicles (SUVs) containing the following lipids: 1,2-dioleoyl-

594 sn-glycero-3-phosphocholine (18:1 DOPC, Avanti # 850375C), 1,2-dioleoyl-*sn*-glycero-3-

595 phospho-L-serine (18:1 DOPS, Avanti # 840035C), 1,2-dioleoyl-sn-glycero-3-

596 phosphoethanolamine-N-[4-(p-maleimidomethyl)cyclohexane-carboxamide] (18:1 MCC-

597 PE, Avanti # 780201C). Lipid compositions reported in figure legends represent the molar

598 percentage of each lipid species.

599 To create SLBs, a total concentration of 0.25 mM lipids was solvated in 1x PBS

600 [pH 7.4] and deposited on Piranha etched glass coverslips (25 x 75 mm) adhered to an

601 IBIDI chamber. After a 30-minute incubation, membranes were washed with 4 mL of 1x

602 PBS [pH 7.4] and then blocked for 10 minutes with 1 mg/mL beta casein (Thermo

603 FisherSci, Cat# 37528) in 1x PBS [pH 7.4] (Corning, Cat# 46-013-CM). To conjugate H-

604 Ras to maleimide lipids (MCC-PE), blocked membranes were incubated with 30 μM H-

605 Ras(GDP) in buffer containing 1x PBS [pH 7.4], 1 mM $MgCl_2$, 50 μM GDP, and 0.1 mM

606 TCEP for 2 hours. The membrane conjugation reaction was terminated after 2 hours with

607 1x PBS [pH 7.4] containing 5 mM β-mercaptoethanol (βME). Membranes were then

608 washed and stored in 1x PBS [pH 7.4] until performing the TIRF-M membrane binding

609 experiments. H-Ras was purified as previously described (Rathinaswamy et al., 2023).

610   To perform the TIRF-M membrane binding assays, 200 nM farnesyl-$G\beta\gamma$ was

611 equilibrated into the supported membranes for 30 minutes. In parallel, nucleotide

612 exchange of H-Ras(GDP) was performed by adding 50 nM guanine nucleotide exchange

613 factor (SosCat) in 1x PBS [pH 7.4], 1 mM $MgCl_2$, 50 μM GDP. To measure membrane

614 binding, Dy647-p84-p110γ was diluted into the following buffer: 20 mM HEPES [pH 7.0],

615 150 mM NaCl, 50 μM GTP, 1 mM ATP, 5 mM $MgCl_2$, 0.5 mM EGTA, 20 mM glucose, 200

616 μg/mL beta casein (ThermoScientific, Cat# 37528), 20 mM BME, 320 μg/mL glucose

617 oxidase (Serva, #22780.01 *Aspergillus niger*), 50 μg/mL catalase (Sigma, #C40-100MG

618 Bovine Liver), and 2 mM Trolox. Trolox was prepared as previously described (Hansen

619 et al., 2019). Perishable reagents (i.e. glucose oxidase, catalase, and Trolox) were added

620 10 minutes before image acquisition.

621   TIRF-M experiments were performed using an inverted Nikon Ti2 microscope with

622 a 100x Nikon (1.49 NA) oil immersion objective. The x-axis and y-axis positions were

623 controlled using a Nikon motorized stage. Dy647-p84-p110γ was excited with a 637 nm

624 diode laser (OBIS laser diode, Coherent Inc. Santa Clara, CA) controlled with an acousto-

625 optic tunable filter (AOTF) and laser launch built by Vortran (Sacramento, CA). The power

626 output measured through the objective for single particle imaging was 1-3 mW. Excitation

627 light passing through quad multi-pass dichroic filter cube (Semrock). Fluorescence

628 emission passed through Nikon emission filter wheel containing the following 25 mm

629 ET700/75M emission filters (Semrock) before being detected on iXion Life 897 EMCCD

630 camera (Andor Technology Ltd., UK). All TIRF-M experiments were performed at room

631 temperature (23°C). Microscope hardware was controlled using Nikon NIS elements.

632 Data analysis was performed using ImageJ/Fiji and Prism graphing program.

633

634 *Cryo-EM Sample Preparation and Data Collection*

635 3 μL of purified nanobody-bound p110γ at 0.45 mg/ml was adsorbed onto C-Flat 2/2-T

636 grids that were glow discharged for 25 s at 15 mA. Grids were then plunged into liquid

637 ethane using a Vitrobot Mark IV (Thermo Fisher Scientific) with the following settings: -5

638 blot force, 1.5 s blot time, 100% humidity and 4 °C. Vitrified specimens were screened for

639 ice and particle quality at the UBC High resolution macromolecular electron microscopy

640 (HRMEM) facility using a 200-kV Glacios transmission electron microscope equipped with

641 a Falcon 3EC direct electron detector (DED). Clipped grids were sent to the Pacific

642 Northwest Cryo-EM Center (PNCC) where 7,322 movies were collected using a Titan

643 Krios equipped with a Gatan K3 DED and a BioQuantum K3 energy filter with a slit width

644 of 20 eV. The movies were collected at a physical pixel size of 0.830 Å/pix and a total

645 dose of $50e^-/Å^2$ over 50 frames.

646

647 *Cryo-EM image analysis*

648 The data were processed using cryoSPARC v.3.3.2 (Punjani et al., 2017). The

649 movies were pre-processed by patch motion correction using default settings except

650 Fourier-cropping by a factor of 2, followed by patch CTF estimation using default settings.

651 A 3D map of PI3K p110γ-p101 complex (EMD-23808) was used to create 2D projections

652 for use as templates to auto-pick 1,463,553 particles. Particles were extracted with a box

653 size of 380 pixels, Fourier cropped to a box size of 96 pixels and subjected to 2D

654 classification. After discarding classes with obvious noise and no features, 795,162

655 particles were used for multiple rounds of *ab initio* reconstruction and heterogeneous

656 refinement using 4 or 5 classes. 365,178 particles, which generated the two best 3D

657 reconstruction, were used to carry out Per-particle local-motion correction with 760 pixels

658 box size later downsized to 380 pixels followed by several rounds of *ab initio*

659 reconstruction and heterogeneous refinement using 3 or 5 classes. 149,603 from best

660 class were further refined by homogeneous refinement and a final Non-Uniform (NU)-

661 refinement which generated a reconstruction with an overall resolution of 3.02 Å based

662 on the Fourier shell correlation (FSC) 0.143 criterion.

663

664 *Building the structural model of p110γ-NB7*

665 The previous structural model of full length p110γ from the complex of p110γ-

666 p101(PDB: 7MEZ) (Rathinaswamy et al., 2021a) was fit into the map using Chimera

667 (Pettersen et al., 2004). A model of the nanobody was generated using Alphafold2 using

668 the Colabfold v1.5.2 server (Mirdita et al., 2022). The CDR loops were removed from this

669 initial model, and the remaining nanobody was fit into the map using Chimera. The final

670 structure was built by iterative rounds of automated model building in Phenix, manual

671 model building in COOT (Emsley et al., 2010), and refinement in

672 Phenix.real_space_refine using realspace, rigid body, and adp refinement with tight

673 secondary structure restraints (Afonine et al., 2012). This allowed for unambiguous

674 building of the CDRs of the nanobody, and their interface with p110γ. The full refinement

675 and validation statistics are shown in Supplemental table 1.

676

677 *Hydrogen Deuterium eXchange Mass Spectrometry*

678 Exchange reactions to assess differences in p110γ upon phosphorylation were

679 carried out at 20°C in 10 μL volumes with final concentrations of 1.6 μM for both apo and

680 phosphorylated p110γ. A total of two conditions were assessed: p110γ apo and PKCβ

681 phosphorylated p110γ. The hydrogen-deuterium exchange reaction was initiated by the

682 addition of 8 μL D$_2$O buffer (94.3% D$_2$O, 100 mM NaCl, 20 mM HEPES pH 7.5) to the 2

683 μL protein for a final D$_2$O concentration of 75.4%. Exchange was carried out over five

684 time points (3s on ice, and 3s, 30s, 300s and 3000s at 20°C) and the reaction was

685 quenched with addition of 60 μL of ice-cold acidic quench buffer (0.7 M guanidine-HCl,

686 1% formic acid). After quenching, samples were immediately frozen in liquid nitrogen and

687 stored at -80°C. All reactions were carried out in triplicate.

688

689 *Protein Digestion and MS/MS Data Collection*: Protein samples were rapidly

690 thawed and injected onto an integrated fluidics system containing a HDx-3 PAL liquid

691 handling robot and climate-controlled chromatography system (LEAP Technologies), a

692 Dionex Ultimate 3000 UHPLC system, as well as an Impact HD QTOF Mass spectrometer

693 (Bruker). The protein was run over two immobilized pepsin columns (Applied Biosystems;

694 Poroszyme™ Immobilized Pepsin Cartridge, 2.1 mm x 30 mm; Thermo-Fisher 2-3131-

695 00; at 10°C and 2°C respectively) at 200 μL/min for 3 minutes. The resulting peptides

696 were collected and desalted on a C18 trap column [Acquity UPLC BEH C18 1.7 mm

697   column (2.1 x 5 mm); Waters 186003975]. The trap was subsequently eluted in line with

698   an ACQUITY 1.7 μm particle, 100 x 1 mm2 C18 UPLC column (Waters 186002352), using

699   a gradient of 3-35% B (buffer A, 0.1% formic acid; buffer B, 100% acetonitrile) over 11

700   min immediately followed by a gradient of 35-80% B over 5 minutes. MS experiments

701   acquired over a mass range from 150 to 2200 mass/charge ratio (m/z) using an

702   electrospray ionization source operated at a temperature of 200°C and a spray voltage of

703   4.5 kV.

704

705   *Peptide Identification*: Peptides were identified using data-dependent acquisition

706   following tandem MS/MS experiments (0.5 s precursor scan from 150-2000 m/z; twelve

707   0.25 s fragment scans from 150-2000 m/z). MS/MS datasets were analyzed using

708   PEAKS7 (PEAKS), and a false discovery rate was set at 0.1% using a database of purified

709   proteins and known contaminants. Same approach was used to identify phosphorylated

710   and non-phosphorylated peptides for our in-vitro phosphorylation experiments, with

711   variable phosphorylation of STY residues was added to the search. The search

712   parameters were set with a precursor tolerance of 20 parts per million, fragment mass

713   error 0.02 Da, and charge states from 1 to 8, with a selection criterion of peptides that

714   had a –10logP score of >24.03 for phosphorylated and >23.05 for non-phosphorylated.

715   The MS/MS spectra of the PKC phosphorylated peptides are included in Fig S3.

716

717   *Mass Analysis of Peptide Centroids and Measurement of Deuterium Incorporation:*

718   HD-Examiner Software (Sierra Analytics) was used to automatically calculate the level of

719   deuterium incorporation into each peptide. All peptides were manually inspected for

720   correct charge state, correct retention time, and appropriate selection of isotopic

721   distribution. Deuteration levels were calculated using the centroid of the experimental

722   isotope clusters. HDX-MS results are presented with no correction for back exchange

723   shown in the Source data, with the only correction being applied correcting for the

724   deuterium oxide percentage of the buffer used in the exchange (75.4%). Changes in any

725   peptide at any time point greater than specified cut-offs (5% and 0.45 Da) and with an

726   unpaired, two-tailed t-test value of $p<0.01$ was considered significant. A number of

727 peptides in the helical domain showed isotope distributions consistent with EX1 H/D

728 exchange. Attempts to define the relative percentages of each population using

729 HDExaminer were extremely noisy, so representative EX1 profiles are shown in Fig. 3C.

730 The raw peptide deuterium incorporation graphs for a selection of peptides with significant

731 differences are shown in Fig. 4D, with the raw data for all analysed peptides in the source

732 data. To allow for visualization of differences across all peptides, we utilized number of

733 deuteron difference (#D) plots (Fig. 4B). These plots show the total difference in

734 deuterium incorporation over the entire H/D exchange time course, with each point

735 indicating a single peptide. The data analysis statistics for all HDX-MS experiments are

736 in Supplemental Table 2 according to the guidelines of (Masson et al., 2019). The mass

737 spectrometry proteomics data have been deposited to the ProteomeXchange Consortium

738 via the PRIDE partner repository (Perez-Riverol et al., 2022) with the dataset identifier

739 PXD040765.

740

References

742 Afonine PV, Grosse-Kunstleve RW, Echols N, Headd JJ, Moriarty NW, Mustyakimov M,
743   Terwilliger TC, Urzhumtsev A, Zwart PH, Adams PD. 2012. Towards automated
744   crystallographic structure refinement with phenix.refine. *Acta Crystallogr D Biol*
745   *Crystallogr* **68**:352–367. doi:10.1107/S0907444912001308
746 Angulo I, Vadas O, Garçon F, Banham-Hall E, Plagnol V, Leahy TR, Baxendale H,
747   Coulter T, Curtis J, Wu C, Blake-Palmer K, Perisic O, Smyth D, Maes M, Fiddler
748   C, Juss J, Cilliers D, Markelj G, Chandra A, Farmer G, Kielkowska A, Clark J,
749   Kracker S, Debré M, Picard C, Pellier I, Jabado N, Morris JA, Barcenas-Morales
750   G, Fischer A, Stephens L, Hawkins P, Barrett JC, Abinun M, Clatworthy M,
751   Durandy A, Doffinger R, Chilvers ER, Cant AJ, Kumararatne D, Okkenhaug K,
752   Williams RL, Condliffe A, Nejentsev S. 2013. Phosphoinositide 3-kinase δ gene
753   mutation predisposes to respiratory infection and airway damage. *Science*
754   **342**:866–871. doi:10.1126/science.1243292
755 Becattini B, Marone R, Zani F, Arsenijevic D, Seydoux J, Montani J, Dulloo A, Thorens
756   B, Preitner F, Wymann M, Solinas G. 2011. PI3Kgamma within a
757   nonhematopoietic cell type negatively regulates diet-induced thermogenesis and
758   promotes obesity and insulin resistance. *Proc Natl Acad Sci USA* **108**:E854-63.
759   doi:10.1073/pnas.1106698108/-/DCSupplemental
760 Bell K, Sunose M, Ellard K, Cansfield A, Taylor J, Miller W, Ramsden N, Bergamini G,
761   Neubauer G. 2012. SAR studies around a series of triazolopyridines as potent
762   and selective PI3Kγ inhibitors. *Bioorg Med Chem Lett* **22**:5257–5263.
763   doi:10.1016/j.bmcl.2012.06.049

764   Bohnacker T, Marone R, Collmann E, Calvez R, Hirsch E, Wymann M. 2009.
765   PI3Kgamma adaptor subunits define coupling to degranulation and cell motility
766   by distinct PtdIns(3,4,5)P3 pools in mast cells. *Sci Signal* **2**:ra27.
767   doi:10.1126/scisignal.2000259
768   Bohnacker T, Prota AE, Beaufils F, Burke JE, Melone A, Inglis AJ, Rageot D, Sele AM,
769   Cmiljanovic V, Cmiljanovic N, Bargsten K, Aher A, Akhmanova A, Díaz JF,
770   Fabbro D, Zvelebil M, Williams RL, Steinmetz MO, Wymann MP. 2017.
771   Deconvolution of Buparlisib's mechanism of action defines specific PI3K and
772   tubulin inhibitors for therapeutic intervention. *Nat Commun* **8**:14683.
773   doi:10.1038/ncomms14683
774   Breasson L, Becattini B, Sardi C, Molinaro A, Zani F, Marone R, Botindari F,
775   Bousquenaud M, Ruegg C, Wymann MP, Solinas G. 2017. PI3Kγ activity in
776   leukocytes promotes adipose tissue inflammation and early-onset insulin
777   resistance during obesity. *Sci Signal* **10**:eaaf2969. doi:10.1126/scisignal.aaf2969
778   Burke JE. 2018. Structural Basis for Regulation of Phosphoinositide Kinases and Their
779   Involvement in Human Disease. *Mol Cell* **71**:653–673.
780   doi:10.1016/j.molcel.2018.08.005
781   Burke JE, Perisic O, Masson GR, Vadas O, Williams RL. 2012. Oncogenic mutations
782   mimic and enhance dynamic events in the natural activation of phosphoinositide
783   3-kinase p110α (PIK3CA). *Proc Natl Acad Sci USA* **109**:15259–15264.
784   doi:10.1073/pnas.1205508109
785   Burke JE, Vadas O, Berndt A, Finegan T, Perisic O, Williams RL. 2011. Dynamics of the
786   phosphoinositide 3-kinase p110δ interaction with p85α and membranes reveals
787   aspects of regulation distinct from p110α. *Structure* **19**:1127–1137.
788   doi:10.1016/j.str.2011.06.003
789   Burke JE, Williams RL. 2015. Synergy in activating class I PI3Ks. *Trends in Biochemical*
790   *Sciences* **40**:88–100. doi:10.1016/j.tibs.2014.12.003
791   Burke JE, Williams RL. 2013. Dynamic steps in receptor tyrosine kinase mediated
792   activation of class IA phosphoinositide 3-kinases (PI3K) captured by H/D
793   exchange (HDX-MS). *Adv Biol Regul* **53**:97–110. doi:10.1016/j.jbior.2012.09.005
794   Campa CC, Silva RL, Margaria JP, Pirali T, Mattos MS, Kraemer LR, Reis DC, Grosa
795   G, Copperi F, Dalmarco EM, Lima-Júnior RCP, Aprile S, Sala V, Dal Bello F,
796   Prado DS, Alves-Filho JC, Medana C, Cassali GD, Tron GC, Teixeira MM,
797   Ciraolo E, Russo RC, Hirsch E. 2018. Inhalation of the prodrug PI3K inhibitor
798   CL27c improves lung function in asthma and fibrosis. *Nat Commun* **9**:5232–16.
799   doi:10.1038/s41467-018-07698-6
800   Camps M, Rückle T, Ji H, Ardissone V, Rintelen F, Shaw J, Ferrandi C, Chabert C,
801   Gillieron C, Françon B, Martin T, Gretener D, Perrin D, Leroy D, Vitte P-A, Hirsch
802   E, Wymann MP, Cirillo R, Schwarz MK, Rommel C. 2005. Blockade of
803   PI3Kgamma suppresses joint inflammation and damage in mouse models of
804   rheumatoid arthritis. *Nat Med* **11**:936–943. doi:10.1038/nm1284
805   De Henau O, Rausch M, Winkler D, Campesato LF, Liu C, Cymerman DH, Budhu S,
806   Ghosh A, Pink M, Tchaicha J, Douglas M, Tibbitts T, Sharma S, Proctor J,
807   Kosmider N, White K, Stern H, Soglia J, Adams J, Palombella VJ, McGovern K,

Kutok JL, Wolchok JD, Merghoub T. 2016. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. *Nature* **539**:443–447. doi:10.1038/nature20554

Deladeriere A, Gambardella L, Pan D, Anderson KE, Hawkins PT, Stephens LR. 2015. The regulatory subunits of PI3Kγ control distinct neutrophil responses. *Sci Signal* **8**:ra8. doi:10.1126/scisignal.2005564

Dornan GL, Siempelkamp BD, Jenkins ML, Vadas O, Lucas CL, Burke JE. 2017. Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in PIK3CD and PIK3R1. *Proc Natl Acad Sci USA* **114**:1982–1987. doi:10.1073/pnas.1617244114

Emsley P, Lohkamp B, Scott WG, Cowtan K. 2010. Features and development of Coot. *Acta Crystallogr D Biol Crystallogr* **66**:486–501. doi:10.1107/S0907444910007493

Evans CA, Liu T, Lescarbeau A, Nair SJ, Grenier L, Pradeilles JA, Glenadel Q, Tibbitts T, Rowley AM, DiNitto JP, Brophy EE, O'Hearn EL, Ali JA, Winkler DG, Goldstein SI, O'Hearn P, Martin CM, Hoyt JG, Soglia JR, Cheung C, Pink MM, Proctor JL, Palombella VJ, Tremblay MR, Castro AC. 2016. Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate. *ACS Med Chem Lett* **7**:862–867. doi:10.1021/acsmedchemlett.6b00238

Gangadhara G, Dahl G, Bohnacker T, Rae R, Gunnarsson J, Blaho S, Öster L, Lindmark H, Karabelas K, Pemberton N, Tyrchan C, Mogemark M, Wymann MP, Williams RL, Perry MWD, Papavoine T, Petersen J. 2019. A class of highly selective inhibitors bind to an active state of PI3Kγ. *Nature Chemical Biology* **15**:348–357. doi:10.1038/s41589-018-0215-0

Hansen SD, Huang WYC, Lee YK, Bieling P, Christensen SM, Groves JT. 2019. Stochastic geometry sensing and polarization in a lipid kinase-phosphatase competitive reaction. *Proc Natl Acad Sci U S A* **116**:15013–15022. doi:10.1073/pnas.1901744116

Hawkins PT, Stephens LR. 2015. PI3K signalling in inflammation. *Biochim Biophys Acta* **1851**:882–897. doi:10.1016/j.bbalip.2014.12.006

Jenkins ML, Ranga-Prasad H, Parson MAH, Harris NJ, Rathinaswamy MK, Burke JE. 2023. Oncogenic mutations of PIK3CA lead to increased membrane recruitment driven by reorientation of the ABD, p85 and C-terminus. *Nat Commun* **14**:181. doi:10.1038/s41467-023-35789-6

Jin JR, Gogvadze E, Xavier AR, Bohnacker T, Voelzmann J, Wymann MP. 2020. PI3Kγ Regulatory Protein p84 Determines Mast Cell Sensitivity to Ras Inhibition-Moving Towards Cell Specific PI3K Targeting? *Front Immunol* **11**:585070. doi:10.3389/fimmu.2020.585070

Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway

852 LA. 2010. COT drives resistance to RAF inhibition through MAP kinase pathway
853 reactivation. *Nature* **468**:968–972. doi:10.1038/nature09627
854 Kaneda MM, Cappello P, Nguyen AV, Ralainirina N, Hardamon CR, Foubert P, Schmid
855 MC, Sun P, Mose E, Bouvet M, Lowy AM, Valasek MA, Sasik R, Novelli F, Hirsch
856 E, Varner JA. 2016a. Macrophage PI3Kγ Drives Pancreatic Ductal
857 Adenocarcinoma Progression. *Cancer Discov* **6**:870–885. doi:10.1158/2159-
858 8290.CD-15-1346
859 Kaneda MM, Messer KS, Ralainirina N, Li H, Leem CJ, Gorjestani S, Woo G, Nguyen
860 AV, Figueiredo CC, Foubert P, Schmid MC, Pink M, Winkler DG, Rausch M,
861 Palombella VJ, Kutok J, McGovern K, Frazer KA, Wu X, Karin M, Sasik R, Cohen
862 EEW, Varner JA. 2016b. PI3Kγ is a molecular switch that controls immune
863 suppression. *Nature* **539**:437–442. doi:10.1038/nature19834
864 Kurig B, Shymanets A, Bohnacker T, Prajwal, Brock C, Ahmadian MR, Schaefer M,
865 Gohla A, Harteneck C, Wymann MP, Jeanclos E, Nürnberg B. 2009. Ras is an
866 indispensable coregulator of the class IB phosphoinositide 3-kinase
867 p87/p110gamma. *Proc Natl Acad Sci USA* **106**:20312–20317.
868 doi:10.1073/pnas.0905506106
869 Laffargue M, Calvez R, Finan P, Trifilieff A, Barbier M, Altruda F, Hirsch E, Wymann
870 MP. 2002. Phosphoinositide 3-kinase gamma is an essential amplifier of mast
871 cell function. *Immunity* **16**:441–451.
872 Lanahan SM, Wymann MP, Lucas CL. 2022. The role of PI3Kγ in the immune system:
873 new insights and translational implications. *Nat Rev Immunol*.
874 doi:10.1038/s41577-022-00701-8
875 Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR,
876 Meyerson M, Gabriel SB, Lander ES, Getz G. 2014. Discovery and saturation
877 analysis of cancer genes across 21 tumour types. *Nature* **505**:495–501.
878 doi:10.1038/nature12912
879 Li H, Prever L, Hirsch E, Gulluni F. 2021. Targeting PI3K/AKT/mTOR Signaling Pathway
880 in Breast Cancer. *Cancers (Basel)* **13**:3517. doi:10.3390/cancers13143517
881 Li Z, Jiang H, Xie W, Zhang Z, Smrcka AV, Wu D. 2000. Roles of PLC-beta2 and -beta3
882 and PI3Kgamma in chemoattractant-mediated signal transduction. *Science*
883 **287**:1046–1049. doi:10.1126/science.287.5455.1046
884 Liu X, Zhou Q, Hart JR, Xu Y, Yang S, Yang D, Vogt PK, Wang M-W. 2022. Cryo-EM
885 structures of cancer-specific helical and kinase domain mutations of PI3Kα. *Proc*
886 *Natl Acad Sci U S A* **119**:e2215621119. doi:10.1073/pnas.2215621119
887 Lucas CL, Kuehn HS, Zhao F, Niemela JE, Deenick EK, Palendira U, Avery DT, Moens
888 L, Cannons JL, Biancalana M, Stoddard J, Ouyang W, Frucht DM, Rao VK,
889 Atkinson TP, Agharahimi A, Hussey AA, Folio LR, Olivier KN, Fleisher TA,
890 Pittaluga S, Holland SM, Cohen JI, Oliveira JB, Tangye SG, Schwartzberg PL,
891 Lenardo MJ, Uzel G. 2014. Dominant-activating germline mutations in the gene
892 encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and
893 human immunodeficiency. *Nat Immunol* **15**:88–97. doi:10.1038/ni.2771
894 Luo L, Wall AA, Tong SJ, Hung Y, Xiao Z, Tarique AA, Sly PD, Fantino E, Marzolo M-P,
895 Stow JL. 2018. TLR Crosstalk Activates LRP1 to Recruit Rab8a and PI3Kγ for

896   Suppression of Inflammatory Responses. *Cell Rep* **24**:3033–3044.
897   doi:10.1016/j.celrep.2018.08.028

898 Mandelker D, Gabelli SB, Schmidt-Kittler O, Zhu J, Cheong I, Huang C-H, Kinzler KW,
899   Vogelstein B, Amzel LM. 2009. A frequent kinase domain mutation that changes
900   the interaction between PI3Kalpha and the membrane. *Proc Natl Acad Sci USA*
901   **106**:16996–17001. doi:10.1073/pnas.0908444106

902 Masson GR, Burke JE, Ahn NG, Anand GS, Borchers C, Brier S, Bou-Assaf GM, Engen
903   JR, Englander SW, Faber J, Garlish R, Griffin PR, Gross ML, Guttman M,
904   Hamuro Y, Heck AJR, Houde D, Iacob RE, Jørgensen TJD, Kaltashov IA,
905   Klinman JP, Konermann L, Man P, Mayne L, Pascal BD, Reichmann D, Skehel
906   M, Snijder J, Strutzenberg TS, Underbakke ES, Wagner C, Wales TE, Walters
907   BT, Weis DD, Wilson DJ, Wintrode PL, Zhang Z, Zheng J, Schriemer DC, Rand
908   KD. 2019. Recommendations for performing, interpreting and reporting hydrogen
909   deuterium exchange mass spectrometry (HDX-MS) experiments. *Nat Methods*
910   **16**:595–602. doi:10.1038/s41592-019-0459-y

911 Miled N, Yan Y, Hon W-C, Perisic O, Zvelebil M, Inbar Y, Schneidman-Duhovny D,
912   Wolfson HJ, Backer JM, Williams RL. 2007. Mechanism of two classes of cancer
913   mutations in the phosphoinositide 3-kinase catalytic subunit. *Science* **317**:239–
914   242. doi:10.1126/science.1135394

915 Mirdita M, Schütze K, Moriwaki Y, Heo L, Ovchinnikov S, Steinegger M. 2022.
916   ColabFold: making protein folding accessible to all. *Nat Methods* **19**:679–682.
917   doi:10.1038/s41592-022-01488-1

918 Okkenhaug K. 2013. Signaling by the phosphoinositide 3-kinase family in immune cells.
919   *Annu Rev Immunol* **31**:675–704. doi:10.1146/annurev-immunol-032712-095946

920 Pacold ME, Suire S, Perisic O, Lara-Gonzalez S, Davis CT, Walker EH, Hawkins PT,
921   Stephens L, Eccleston JF, Williams RL. 2000. Crystal structure and functional
922   analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. *Cell*
923   **103**:931–943.

924 Perez-Riverol Y, Bai J, Bandla C, García-Seisdedos D, Hewapathirana S,
925   Kamatchinathan S, Kundu DJ, Prakash A, Frericks-Zipper A, Eisenacher M,
926   Walzer M, Wang S, Brazma A, Vizcaíno JA. 2022. The PRIDE database
927   resources in 2022: a hub for mass spectrometry-based proteomics evidences.
928   *Nucleic Acids Res* **50**:D543–D552. doi:10.1093/nar/gkab1038

929 Perino A, Ghigo A, Ferrero E, Morello F, Santulli G, Baillie GS, Damilano F, Dunlop AJ,
930   Pawson C, Walser R, Levi R, Altruda F, Silengo L, Langeberg LK, Neubauer G,
931   Heymans S, Lembo G, Wymann MP, Wetzker R, Houslay MD, Iaccarino G, Scott
932   JD, Hirsch E. 2011. Integrating Cardiac PIP(3) and cAMP Signaling through a
933   PKA Anchoring Function of p110gamma. *Mol Cell* **42**:84–95.
934   doi:10.1016/j.molcel.2011.01.030

935 Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin
936   TE. 2004. UCSF Chimera--a visualization system for exploratory research and
937   analysis. *J Comput Chem* **25**:1605–1612. doi:10.1002/jcc.20084

938   Punjani A, Rubinstein JL, Fleet DJ, Brubaker MA. 2017. cryoSPARC: algorithms for
939   rapid unsupervised cryo-EM structure determination. *Nat Methods* **14**:290–296.
940   doi:10.1038/nmeth.4169
941   Rathinaswamy MK, Burke JE. 2019. Class I phosphoinositide 3-kinase (PI3K)
942   regulatory subunits and their roles in signaling and disease. *Adv Biol Regul*
943   100657. doi:10.1016/j.jbior.2019.100657
944   Rathinaswamy MK, Dalwadi U, Fleming KD, Adams C, Stariha JTB, Pardon E, Baek M,
945   Vadas O, DiMaio F, Steyaert J, Hansen SD, Yip CK, Burke JE. 2021a. Structure
946   of the phosphoinositide 3-kinase (PI3K) p110γ-p101 complex reveals molecular
947   mechanism of GPCR activation. *Sci Adv* **7**:eabj4282. doi:10.1126/sciadv.abj4282
948   Rathinaswamy MK, Fleming KD, Dalwadi U, Pardon E, Harris NJ, Yip CK, Steyaert J,
949   Burke JE. 2021b. HDX-MS-optimized approach to characterize nanobodies as
950   tools for biochemical and structural studies of class IB phosphoinositide 3-
951   kinases. *Structure* **29**:1371-1381.e6. doi:10.1016/j.str.2021.07.002
952   Rathinaswamy MK, Gaieb Z, Fleming KD, Borsari C, Harris NJ, Moeller BE, Wymann
953   MP, Amaro RE, Burke JE. 2021c. Disease-related mutations in PI3Kγ disrupt
954   regulatory C-terminal dynamics and reveal a path to selective inhibitors. *Elife*
955   **10**:e64691. doi:10.7554/eLife.64691
956   Rathinaswamy MK, Jenkins ML, Duewell BR, Zhang X, Harris NJ, Evans JT, Stariha
957   JTB, Dalwadi U, Fleming KD, Ranga-Prasad H, Yip CK, Williams RL, Hansen
958   SD, Burke JE. 2023. Molecular basis for differential activation of p101 and p84
959   complexes of PI3Kγ by Ras and GPCRs. *Cell Rep* **42**:112172.
960   doi:10.1016/j.celrep.2023.112172
961   Rynkiewicz NK, Anderson KE, Suire S, Collins DM, Karanasios E, Vadas O, Williams R,
962   Oxley D, Clark J, Stephens LR, Hawkins PT. 2020. Gβγ is a direct regulator of
963   endogenous p101/p110γ and p84/p110γ PI3Kγ complexes in mouse neutrophils.
964   *Sci Signal* **13**:eaaz4003. doi:10.1126/scisignal.aaz4003
965   Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell
966   S, Riggins G, Willson J, Markowitz S, Kinzler K, Vogelstein B, Velculescu V.
967   2004. High frequency of mutations of the PIK3CA gene in human cancers.
968   *Science* **304**:554. doi:10.1126/science.1096502
969   Shymanets A, Prajwal P, Bucher K, Beer-Hammer S, Harteneck C, Nürnberg B. 2013.
970   p87 and p101 subunits are distinct regulators determining class IB PI3K
971   specificity. *J Biol Chem* **288(43)**:31059–68. doi:10.1074/jbc.M113.508234
972   Siempelkamp BD, Rathinaswamy MK, Jenkins ML, Burke JE. 2017. Molecular
973   mechanism of activation of class IA phosphoinositide 3-kinases (PI3Ks) by
974   membrane-localized HRas. *J Biol Chem* **292**:12256–12266.
975   doi:10.1074/jbc.M117.789263
976   Stephens LR, Eguinoa A, Erdjument-Bromage H, Lui M, Cooke F, Coadwell J, Smrcka
977   AS, Thelen M, Cadwallader K, Tempst P, Hawkins PT. 1997. The Gbg sensitivity
978   of a PI3K is dependent upon a tightly associated adaptor, p101. *Cell* **89**:105–114.
979   Takeda AJ, Maher TJ, Zhang Y, Lanahan SM, Bucklin ML, Compton SR, Tyler PM,
980   Comrie WA, Matsuda M, Olivier KN, Pittaluga S, McElwee JJ, Long Priel DA,
981   Kuhns DB, Williams RL, Mustillo PJ, Wymann MP, Koneti Rao V, Lucas CL.

982 2019. Human PI3Kγ deficiency and its microbiota-dependent mouse model
983 reveal immunodeficiency and tissue immunopathology. *Nat Commun* **10**:4364–
984 12. doi:10.1038/s41467-019-12311-5

985 Vadas O, Dbouk HA, Shymanets A, Perisic O, Burke JE, Abi Saab WF, Khalil BD,
986 Harteneck C, Bresnick AR, Nürnberg B, Backer JM, Williams RL. 2013.
987 Molecular determinants of PI3Kγ-mediated activation downstream of G-protein-
988 coupled receptors (GPCRs). *Proc Natl Acad Sci U S A* **110**:18862–18867.
989 doi:10.1073/pnas.1304801110

990 Vanhaesebroeck B, Perry MWD, Brown JR, André F, Okkenhaug K. 2021. PI3K
991 inhibitors are finally coming of age. *Nat Rev Drug Discov* **20**:741–769.
992 doi:10.1038/s41573-021-00209-1

993 Vasan N, Cantley LC. 2022. At a crossroads: how to translate the roles of PI3K in
994 oncogenic and metabolic signalling into improvements in cancer therapy. *Nat*
995 *Rev Clin Oncol*. doi:10.1038/s41571-022-00633-1

996 Walker EH, Perisic O, Ried C, Stephens L, Williams RL. 1999. Structural insights into
997 phosphoinositide 3-kinase catalysis and signalling. *Nature* **402**:313–320.
998 doi:10.1038/46319

999 Walser R, Burke JE, Gogvadze E, Bohnacker T, Zhang X, Hess D, Küenzi P, Leitges M,
1000 Hirsch E, Williams RL, Laffargue M, Wymann MP. 2013. PKCβ phosphorylates
1001 PI3Kγ to activate it and release it from GPCR control. *PLoS Biol* **11**:e1001587.
1002 doi:10.1371/journal.pbio.1001587

1003 Zhang X, Vadas O, Perisic O, Anderson KE, Clark J, Hawkins PT, Stephens LR,
1004 Williams RL. 2011. Structure of lipid kinase p110β/p85β elucidates an unusual
1005 SH2-domain-mediated inhibitory mechanism. *Mol Cell* **41**:567–578.
1006 doi:10.1016/j.molcel.2011.01.026

1007

1008

1009

1010

1011

1012

1013

1014

1015

1016

1017

1018

1019

Figures and Figure Legends

Figure 1. The inhibitory nanobody NB7 binds tightly to all p110γ complexes and inhibits kinase activity, but does not prevent membrane binding

A. Cartoon schematic depicting nanobody inhibition of activation by lipidated Gβγ (1.5 μM final concentration). Lipid kinase assays show a potent inhibition of lipid kinase activity with increasing concentrations of NB7 (3-3000 nM) for the different complexes. The protein concentration of p110γ (300 nM), p110γ-p84 (330 nM) and p110γ-p101 (12 nM) was different due to intrinsic differences of each complex to be activated by lipidated Gβγ.

B. Association and dissociation curves for the dose response of His-NB7 binding to p110γ, p110γ-p84 and p110γ-p101 (50 – 1.9 nM) is shown. A cartoon schematic of BLI analysis of the binding of immobilized His-NB7 to p110γ is shown on the left. Dissociation constants (K_D) were calculated based on a global fit to a 1:1 model for the top three concentrations and averaged with error shown.

35

1033 **B**. Association and dissociation curves for His-NB7 binding to p110γ, p110α-p85α, p110β-p85β, and

1034 p110δ-p85β. Experiments were performed in duplicate with a final concentration of 50 nM of each class I

1035 PI3K complex.

1036 **D**. Total Internal Reflection Fluorescence Microscopy (TIRF-M) analysis of the effect of nanobody NB7 on

1037 PI3K recruitment to supported lipid bilayers containing H-Ras(GTP) and farnesyl-Gβγ. Y647-p84/p110γ

1038 displays rapid equilibration kinetics and is insensitive to the addition of 500 nM nanobody (black arrow,

1039 250 sec) on supported lipid bilayers containing H-Ras(GTP) and farnesyl-Gβγ.

1040 **E**. Kinetics of 50 nM DY647-p84/p110γ membrane recruitment appears indistinguishable in the absence

1041 and presence of nanobody. Prior to sample injection, DY647-p84/p110γ was incubated for 10 minutes

1042 with 500 nM nanobody.

1043 **F**. Representative TIRF-M images showing the localization of 50 nM DY647-p84/p110γ visualized in the

1044 absence or presence of 500 nM nanobody (+NB7). Membrane composition for panels C-E: 93% DOPC,

1045 5% DOPS, 2% MCC-PE, Ras(GTP) covalently attached to MCC-PE, and 200 nM farnesyl-Gβγ.

1046

1047

1048

1049

1050

1051

1052

1053

1054

1055

1056

1057

1058

1059

Figure 2. Structure of p110γ bound to inhibitory nanobody NB7

A. Domain schematics of p110γ with helical domain (blue), activation loop (orange), and regulatory motif (green) of p110 annotated.

**B.** Density map of the p110γ-NB7 complex colored according to the schematic in **A**.

C. Cartoon model of the structure of p110γ bound to NB7 colored according to **A**.

D. Schematic depicting the key features of p110 and the nanobody binding site, colored according to panel **A**.

E. Domain schematic of NB7 CDR regions and their sequences.

F. Zoom in on the binding interface of NB7, with the CDRs colored as in panel E, and the electron density of the CDR regions contoured at 3σ (blue mesh).

Figure 3. PKC leads to dual phosphorylation of internal sites in the helical domain, with selectivity for apo p110γ and p110γ-p84 over p110γ-p101.

A. Putative phosphorylation sites mapped on the structure of p110γ (PDB: 7MEZ) and cartoon schematic. The regions are colored based on domain schematics featured in Fig 2A.

B. Raw MS spectra of the unphosphorylated and phosphorylated peptide for a region spanning 579-592 (RYESLKHPKAYPKL) and 593-607 (FSSVKWGQQEIVAKT).

C-E. Extracted traces and ratios of the intensity of extracted ion traces of different phosphorylation site peptides (Top to bottom: S594/S595 and S582) from © p110γ, (**D**) p110γ/p84 or (**E**) p110γ/p101 samples treated with increasing concentration of PKCb according to the legend.

38

Figure 4. Activating phosphorylation at the helical domain leads to opening of the regulatory motif

A. HDX-MS comparing apo and phosphorylated p110γ. Significant differences in deuterium exchange are mapped on to the structure and cartoon of p110γ according to the legend (PDB: 7MEZ).

B. The graph of the #D difference in deuterium incorporation for p110γ, with each point representing a single peptide. Peptides colored in red are those that had a significant change in the mutants (greater than 0.4 Da and 5% difference at any timepoint, with a two tailed t-test p<0.01). Error bars are S.D. (n=3).

C. Representative bimodal distribution (EX1 kinetics) observed in the helical domain peptides of p110γ.

D. Representative p100γ peptides displaying increases in exchange in the phosphorylated state are shown. For all panels, error bars show SD (n = 3)

E. Lipid kinase activity assays of phosphorylated and non-phosphorylated p100γ (concentration, 12nM to 1000nM) ATPase activity (left) and membrane (5% phosphatidylinositol 4,5-bisphosphate (PIP2), 95% phosphatidylserine (PS)) activation (right). Significance is indicated by **(<0.001%), and ***(<0.0001%).

39

Figure 5. Nanobody NB7 blocks PKC phosphorylation, and phosphorylation prevents nanobody binding.

A. Graph showing the intensities of phosphorylated and non-phosphorylated p110γ peptide (593-607) for PKC (500 nM) treated p110γ (black), PKC treated p110γ with NB7 (red) and PKC treated p110γp101 (purple). Scatter plot showing the percent phosphorylation of each complex from the left graph for the indicated peptide (n=3, right). Significance is indicated by ***(<0.0001%).

B. Graph showing the intensities of phosphorylated and non-phosphorylated p110γ peptide (579-592) for PKC treated p110γ (black), PKC treated p110γ with NB7 (red) and PKC treated p110γp101 (purple). Scatter plot showing the percent phosphorylation of each complex from the left graph for the indicated peptide (n=3, right). Significance is indicated by * (<0.01%), and ***(<0.0001%).

C. Cartoon schematic of BLI analysis of the binding of immobilized His-NB7 to phosphorylated and non-phosphorylated p110γ.

**D.** Association curves for phosphorylated and non-phosphorylated p110γ (25nM) binding to His-NB7 are shown (n=3).

E. Kinase activity assays comparing the activation/inhibition of phosphorylated and non-phosphorylated p110γ (concentration, 12nM to 1000nM) with or without nanobody (3000nM final). Significance is indicated by * (<0.05%), and NS (>0.05%).

40

Figure 6. Comparison of nanobody binding site compared to p85 inhibition of class IA PI3Ks and class IB activation sites

A. Comparison of the nanobody NB7 binding site in p110γ compared to the nSH2 inhibitory site in p110α (PDB: 3HHM) (Mandelker et al., 2009)

B. Comparison of the nanobody NB7 binding site in p110γ compared to the X-ray structure of the Ras binding site (PDB: 1HE8) (Pacold et al., 2000) and the Alphafold model of Gβγ bound to p110γ (Rathinaswamy et al., 2023).

 C. Oncogenic mutations and post-translational modifications in spatial proximity to the nanobody binding site.

41

1132   # Supplemental information for:

1133

1134   # Allosteric activation or inhibition of PI3Kγ mediated through

1135   # conformational changes in the p110γ helical domain

1136

1137   Noah J Harris[1*], Meredith L Jenkins[1*], Sung-Eun Nam, Manoj K Rathinaswamy[1],

1138   Matthew Parson[1], Harish Ranga-Prasad[1], Udit Dalwadi[2], Brandon E Moeller[1], Eleanor

1139   Sheekey[1], Scott D Hansen[3], Calvin K Yip[2%], and John E Burke[1,2%]

1140

1141

1142   [1]Department of Biochemistry and Microbiology, University of Victoria, Victoria, British

1143   Columbia, V8W 2Y2, Canada

1144   [2]Department of Biochemistry and Molecular Biology, The University of British Columbia,

1145   Vancouver, British Columbia V6T 1Z3, Canada

1146   [3]Institute of Molecular Biology, University of Oregon, Eugene, OR 97403

1147

1148   *These authors contributed equally

1149   %To whom correspondence should be addressed: John E. Burke

1150   Tel: 1-250-721-8732, email: jeburke@uvic.ca

1151   Calvin K Yip

1152   Tel: 1-604-827-3976, em ail: calvin.yip@ubc.ca

1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163

1164
Figure S1. p110γ-NB7 complex cryo-EM analysis workflow (related to main figure 2): cryo-EM
processing workflow of p110γ-NB7 complex are shown in order of a representative micrographs,
representative 2D classification and 3D reconstruction processing strategy. Bottom left shows Gold-
standard Fourier shell Correlation (FSC) curve of final round on non-uniform homogenous refinement.

Figure S2. Comparison of full length p110γ bound to NB7 compared to p110γ-p101 (related to main figure 2): The structure of the p110γ-p101 complex (PDB:7MEZ) compared to the NB7-p110γ complex is shown colored according to B factor based on the legend.

Figure S3 (related to main figure 3). MS/MS spectra of peptides spanning S582 and S594/S595 for both phosphorylated and unphosphorylated states. The theoretical and experimental mass are annotated for all peptides.

1195

1196 **Supplementary table 1.** Cryo-EM data collection, refinement and validation statistics

1197 **(related to main figure 2)**

	p110γ-NB7 EMD- 27627 PDB: 8DP0
Data collection and processing	
Magnification	
Voltage (kV)	300
Electron exposure (e/ Å^2)	50
Defocus range (nM)	500-2500
Pixel size (Å)	
Symmetry imposed	C1
Initial particle images (no.)	795,162
Final particle images (no.)	149,603
Map resolution (Å)	3.02
FSC threshold	0.143
Map resolution range (Å)	2.6-4.4
Refinement	
Initial model used (PDB)	7MEZ (p110γ only)
Model Resolution (Å)	3.02
FSC threshold	0.5
Map sharpening B factor	Sharpened locally
Model composition	
Non-hydrogen atoms	8737
Protein residues	1,066
Ligands	0
B-factors	
Protein	52.4
Validation	
Mol probability score	1.29
Clashscore	5.33
Poor rotamers (%)	0.0
Ramachandran	
Favored	98.41
Allowed	1.59
Outliers	0.0
R.m.s. deviations	
Bond lengths (Å)	0.002
Bond angles (°)	0.490
Model to map fit (CC_mask)	0.86

1198

1199

1200

1201

1202

1203

1204

1205 **Supplementary table 2.** HDX-MS data collection and validation statistics

1206 **(related to main figure 4)**

Data set	p110γ unphosphorylated	p110γ phosphorylated
HDX reaction details	%D$_2$O=75.5% pH$_{(read)}$=7.5 Temp=4ºC, 20ºC	%D$_2$O=75.5% pH(read)=7.5 Temp=4ºC, 20ºC
HDX time course (seconds)	3s at 4ºC, 3s, 30s, 300s, 3000s at 20 ºC	3s at 4ºC, 3s, 30s, 300s, 3000s at 20 ºC
HDX controls	N/A	N/A
Back-exchange	No correction, deuterium levels are relative	No correction, deuterium levels are relative
Number of peptides	244	244
Sequence coverage	98.4%	98.4%
Average peptide /redundancy	Length= 15.2 Redundancy= 3.3	Length= 15.2 Redundancy= 3.3
Replicates	3	3
Repeatability	Average StDev=0.53%	Average StDev=0.57%
Significant differences in HDX	>5% and >0.4 Da and unpaired t-test ≤0.01	>5% and >0.4 Da and unpaired t-test ≤0.01

1207

47